Search International and National Patent Collections

1. (WO2018126897) APPLICATION OF SODIUM 5-BROMO-2-(α-HYDROXYPENTYL) BENZOATE IN DRUGS TREATING CARDIOVASCULAR DISEASE

Pub. No.:    WO/2018/126897    International Application No.:    PCT/CN2017/117605
Publication Date: Fri Jul 13 01:59:59 CEST 2018 International Filing Date: Fri Dec 22 00:59:59 CET 2017
IPC: C07C 65/03
C07C 51/09
A61K 31/192
A61P 9/00
Applicants: ZHENG ZHOU UNIVERSITY
郑州大学
HENAN METAB BIOPHARMA CO.,LTD
河南美泰宝生物制药有限公司
Inventors: CHANG, Junbiao
常俊标
ZHAO, Wen
赵文
SONG, Chuan Jun
宋传军
Title: APPLICATION OF SODIUM 5-BROMO-2-(α-HYDROXYPENTYL) BENZOATE IN DRUGS TREATING CARDIOVASCULAR DISEASE
Abstract:
Disclosed is an application of sodium 5-bromo-2-(α-hydroxypentyl) benzoate (BZP) in drugs treating cardiovascular disease, belonging to the field of pharmaceutical chemistry. Experiments show that BZP has a protective effect with regard to acute and chronic myocardial ischaemia-reperfusion injury in mice, BZP oral administration and intravenous injection reduce animal overall acute myocardial infarction areas, and BZP reduces isolated perfused heart acute ischaemia-reperfusion injury myocardial infarction areas in mice, thereby improving myocardial contractile function and reducing haematological myocardial injury markers. In addition, BZP chronic oral administration delays the progress of cardiac hypertrophy changing to heart failure after acute myocardial infarction in mice, reduces ventricular remodelling caused by ischaemic heart disease in mice, and significantly improves heart function treatment effects. Furthermore, BZP temporarily reduces the blood pressure of hypertensive rats (SHR rats). These effects show that BZP has effective clinical research and development prospects for drugs protecting against acute and chronic myocardial infarction myocardial injury.